# Clinical Study to Investigate the Efficacy and Safety of NT 201 Compared to Placebo in the Treatment of Chronic Troublesome Drooling Associated With Neurological Disorders and/or Intellectual Disability

Study · id `cardio:ct-nct02270736` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02270736](<https://clinicaltrials.gov/study/NCT02270736>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02270736

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 256 participants.

## Technical summary

Registry record NCT02270736. Randomized; double masking; primary purpose treatment. Start 2015-02-09 (actual); primary completion 2018-02-23 (actual). Results posted on 2021-01-20.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 256 participants (enrolled count; ClinicalTrials.gov record NCT02270736, source copy `cardio:ctgov-nct02270736-2021-08-10`, retrieved 2026-10-26)
- Started: 2015-02-09 (actual) (ClinicalTrials.gov record NCT02270736, source copy `cardio:ctgov-nct02270736-2021-08-10`, retrieved 2026-10-26)
- Primary completion: 2018-02-23 (actual) (ClinicalTrials.gov record NCT02270736, source copy `cardio:ctgov-nct02270736-2021-08-10`, retrieved 2026-10-26)
- Completion: 2019-05-07 (actual) (ClinicalTrials.gov record NCT02270736, source copy `cardio:ctgov-nct02270736-2021-08-10`, retrieved 2026-10-26)
- Results first posted: 2021-01-20 (ClinicalTrials.gov record NCT02270736, source copy `cardio:ctgov-nct02270736-2021-08-10`, retrieved 2026-10-26)
- Countries: Georgia; Hungary; Poland; Russia; Serbia; Ukraine (ClinicalTrials.gov record NCT02270736, source copy `cardio:ctgov-nct02270736-2021-08-10`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02270736-2021-08-10`, retrieved 2026-10-26)

## The registry's words

- Brief title: Clinical Study to Investigate the Efficacy and Safety of NT 201 Compared to Placebo in the Treatment of Chronic Troublesome Drooling Associated With Neurological Disorders and/or Intellectual Disability
- Acronym: SIPEXI
- Condition: Chronic Troublesome Sialorrhea
- Condition: Cerebral Palsy
- Condition: Stroke
- Condition: Traumatic Brain Injury
- Condition: Intellectual Disability
- Intervention (Drug): NT 201 Placebo
- Intervention (Drug): NT 201
- Lead sponsor: Merz Pharmaceuticals GmbH
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Stroke (`core:stroke`)

## Provenance

Content hash: 1388c4774833f67c2fffe54ba22776a9ae3602523751247471e0d65e6c76e7bc
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
